. Company profile
. Main business
is a high-tech enterprise focusing on recombinant protein application solutions. Its main business is the research, development, production and sales of targets and factor proteins, recombinant antibodies, enzymes and reagents, and provides related technical services.
As an upstream supplier in the fields of medical health and life sciences, the company is committed to providing downstream customers with timely, stable and high-quality products and services, and helping global biomedical enterprises and research institutions to innovate and upgrade technology and product innovation and upgrade.
During the reporting period, the company's main business income was divided into the following according to business type:
. Industry analysis
1, recombinant protein industry
According to Frost&Sullivan on the global recombinant protein market size analysis and forecast, the global recombinant protein market grew from US$7 billion in 2015 to US$10.8 billion in 2020, with an annual compound growth rate of 9.0%.
is expected to reach US$20.8 billion in 2025, with an annual compound growth rate of nearly 14.1% from 2020 to 2025.
With the vigorous development of the domestic biopharmaceutical industry and the impact of the new crown epidemic, the recombinant protein market has a strong development momentum.
According to Frost&Sullivan's market size analysis and predictions on domestic recombinant proteins, the domestic recombinant protein market size increased from RMB 5.1 billion in 2015 to RMB 14.54 billion in 2020.
CAGR during the period is 23.3%, and the market size is expected to reach RMB 33.77 billion in 2025, with an annual compound growth rate of nearly 18.4% from 2020 to 2025.
In recent years, the country has continuously issued various regulations, policies and guiding documents for the field of biomedicine, striving to accelerate the cultivation of a group of high-tech biotechnology enterprises and emerging industries with strong international competitiveness. The country's strong support for life and health, biomanufacturing, and biomedicine has driven the rapid development of domestic related industries.
In addition, driven by factors such as the impact of the outbreak of the new crown epidemic on the supply chain, changes in international relations, the import of various raw materials has been hindered, and the endogenous demand has expanded, further promoting the development of local enterprises.
As local enterprises achieve improvement in scientific research capabilities, product quality, and business level in the research and development and production of recombinant proteins, domestic recombinant proteins and other biological research reagents will enhance market competitiveness through the advantages of prices, supply chains and services, gradually break the industry situation dominated by imported products, and form an import substitution development trend.
2, biopharmaceutical industry
With the continuous innovation and breakthroughs in biotechnology, the actual clinical demand continues to increase, the per capita disposable income of residents in the country has increased year by year, and the national encouragement and support policies have been introduced one after another, the biopharmaceutical industry and antibody drug market have developed rapidly.
Technological progress has improved the drug discovery capabilities, and more and more new drug targets are expected to be discovered and applied in clinical treatment to drive new growth in the antibody drug industry.
At the same time, the launch of patient assistance projects and the increasing number of innovative biological drugs being included in the national medical insurance drug catalog have also increased the affordability of biological drugs.
In addition, in recent years, the country has also vigorously promoted the research and development of biopharmaceuticals from a policy level, further driving the development of the biopharmaceutical industry.
Although the development of the domestic biopharmaceutical industry lags behind the global market, biopharmaceuticals are more specific, have clearer mechanisms, and are less likely to develop drug resistance than chemical drugs and traditional Chinese medicines, and can better meet clinical needs.
With the continuous breakthroughs in domestic biotechnology, the gradual adjustment of the industrial structure, and the continuous increase in per capita disposable income of residents, the domestic biopharmaceutical industry has developed strongly in recent years, and the growth rate of the scale of the biopharmaceutical market is much faster than that of the domestic overall pharmaceutical market and other segments.
According to Frost&Sullivan data, from 2016 to 2020, the size of the domestic biopharmaceutical market increased from RMB 183.6 billion to RMB 369.7 billion, with a compound annual growth rate of 19.1%.
is expected to reach RMB 812.2 billion by 2025, and RMB 1.3 trillion by 2030.
3. Comparative analysis of companies in the same industry
(1) Comparative analysis of companies in the same industry debt repayment ability :
At the end of each period of the reporting period, the company and peers were involved in each period. Comparative companies in the industry current ratio , quick ratio situation, for example:
(2) Comparative analysis of profitability of companies in the same industry:
During the reporting period, the company and The comprehensive gross profit margin pairs of the main business of comparable companies in the same industry are as follows:
. Financial status
Performance status: html ml4 From 2018 to the end of 2021, the company's total operating income was RMB 26.0046 million, RMB 35.9832 million, RMB 179.841 million, and RMB 341.8959 million, respectively, with an average annual compound growth rate of 90.42% from 2018 to 2021; net profit attributable to shareholders was RMB -12.3825 million, RMB -8.4983 million, RMB 83.0463 million, and RMB 149.0056 million, respectively.
Accounts receivable:
Fee:
Cash flow :
. Recruitment use
